Guide · Updated November 2026

GLP-1 and Pancreatitis Risk: Separating Fact From Fear

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) carry an acute pancreatitis warning on their FDA labels, but the rates in weight-loss trials are low. In two pooled Zepbound weight-loss trials, 0.2% of people on tirzepatide and 0.2% on placebo had acute pancreatitis confirmed by adjudication. In Wegovy weight-loss trials, it was confirmed in 4 people on semaglutide and 1 on placebo. The risk is real but rare. If pancreatitis is suspected, the labels say to stop the drug.

What the GLP-1 Pancreatitis Risk Actually Looks Like in Data

Pancreatitis is the scariest item on the GLP-1 warning label. I remember reading the Mounjaro prescribing information before my first injection and feeling a knot in my stomach that had nothing to do with nausea. But the fear and the data tell very different stories.

GLP-1 receptor agonists work by mimicking incretin hormones that stimulate insulin release from the pancreas. Because they act on the pancreas, the theoretical concern makes sense. That is why every GLP-1 medication label includes a warning about acute pancreatitis in its warnings and precautions section.

But theory and outcomes are different things. The large trials, each enrolling thousands of patients, show low pancreatitis rates.

Tirzepatide (Zepbound and Mounjaro)

The Zepbound prescribing information pools two weight-loss trials, including SURMOUNT-1 (2,539 adults, 72 weeks). In that pool, 0.2% of tirzepatide patients had acute pancreatitis confirmed by adjudication (0.14 per 100 patient-years), versus 0.2% of placebo patients (0.15 per 100 patient-years).

For context, common side effects were far more frequent. In the same pooled trials, nausea affected 28% and diarrhea 23% of people on the 15 mg dose. Pancreatitis was rare by comparison.

Semaglutide (Wegovy and Ozempic)

The Wegovy prescribing information reports that in weight-loss trials in adults, acute pancreatitis was confirmed by adjudication in 4 Wegovy patients (0.2 cases per 100 patient-years) and 1 placebo patient (less than 0.1 cases per 100 patient-years). The STEP 1 trial (1,961 adults, 68 weeks) was one of these trials. Its mean weight change was -14.9% on semaglutide.

In diabetes trials, the Ozempic prescribing information reports adjudicated acute pancreatitis in 7 Ozempic patients (0.3 cases per 100 patient-years) versus 3 comparator patients (0.2 cases per 100 patient-years).

What These Numbers Mean

The trial rates on the drug are close to the rates on placebo or comparator drugs. That does not mean zero risk. Trials can miss rare effects, and the labels note fatal and non-fatal cases reported with GLP-1 receptor agonists. It means the added risk from the drug, if any, is small for most people.

Why the Pancreatitis Warning Exists Despite Low Rates

If the numbers are this low, why does every GLP-1 carry a pancreatitis warning? Three reasons.

Early signals from diabetes drugs. The first GLP-1 receptor agonists were approved for type 2 diabetes, and post-marketing reports flagged pancreatitis cases. Type 2 diabetes itself raises pancreatitis risk, which made those early reports hard to interpret.

The controversy grew loud enough that the FDA and the European Medicines Agency each ran a full review of the evidence, then took the unusual step of publishing a joint assessment in the New England Journal of Medicine in 2014, with the FDA’s Amy G. Egan as lead author. The two agencies concluded that “recently expressed assertions concerning a causal association between incretin-based drugs and pancreatitis or pancreatic cancer are inconsistent with the current data” (N Engl J Med, 2014, as excerpted by PACE-CME). That assessment predates semaglutide and tirzepatide for weight loss, but it covers the same drug class.

Mechanism of action. These drugs act on the pancreas, so regulators take a cautious approach even when trial rates are low.

Post-marketing pharmacovigilance. The FDA Adverse Event Reporting System (FAERS) collects voluntary reports from patients and doctors. GLP-1 medications have accumulated pancreatitis reports, but FAERS data has a fundamental limitation: it captures reports, not rates. A million prescriptions will generate more reports than a thousand, even if the actual rate is the same. Because GLP-1 prescriptions have surged, report counts can rise without a higher per-patient risk.

Who Faces Higher GLP-1 Pancreatitis Risk

Not everyone starts from the same baseline. Certain groups should have a more detailed conversation with their prescriber before starting a GLP-1.

History of pancreatitis. This is the big one. A past episode is not listed as a contraindication on the current Zepbound, Wegovy, or Ozempic labels. But the labels tell prescribers to watch for symptoms after starting and to stop the drug if pancreatitis is suspected. If you have had pancreatitis, tell your prescriber so they can weigh the risk.

Gallstones. The NIDDK says gallstones are the most common cause of acute pancreatitis. GLP-1 medications are linked to more gallbladder problems: in Wegovy weight-loss trials, cholelithiasis was reported in 1.6% of Wegovy patients versus 0.7% on placebo. See our guide to gallbladder problems on GLP-1s.

Heavy alcohol use. NIDDK lists heavy alcohol use among the most common causes of pancreatitis. Many people on GLP-1s report reduced interest in alcohol, but heavy drinkers should know they are stacking risk factors.

Type 2 diabetes. Diabetes itself is linked to pancreatitis. This complicates the picture because GLP-1s were first developed for diabetes, and early reports likely reflected the disease as well as the drug.

Compare GLP-1 providers

Browse Provider Directory →

Warning Signs: What Pancreatitis Actually Feels Like

I have been on Mounjaro long enough to know what GLP-1 side effects feel like. Nausea. Bloating. Occasional stomach pain after eating too fast. Pancreatitis is different. Recognizing the difference matters.

Pancreatitis symptoms, per the FDA labels and NIDDK:

Persistent or severe pain in the upper abdomen, sometimes spreading to the back
Pain that can start slowly or suddenly and last for days
Nausea and vomiting that are worse than typical GLP-1 nausea
Fever or chills
Racing heartbeat
Swollen or tender abdomen
Yellowing of the skin or eyes

How it differs from common GLP-1 side effects:

Symptom	Typical GLP-1 Side Effect	Pancreatitis Warning Sign
Nausea	Mild to moderate, comes and goes	Severe or persistent, with vomiting
Abdominal pain	Crampy, related to eating	Severe upper abdominal pain, may spread to the back
Fever	Not typical	Can be present
Duration	Usually eases between doses	Persistent, may last days

If you have severe upper abdominal pain, especially if it spreads to your back or comes with vomiting or fever, get urgent care. Do not wait for your next telehealth appointment. Pancreatitis needs prompt diagnosis and treatment.

What to Do If You Have Risk Factors

Having a risk factor does not automatically mean you cannot use a GLP-1. It means you and your prescriber need to weigh it.

Before starting treatment:

Tell your provider about any history of pancreatitis, gallbladder disease, or heavy alcohol use
Ask whether any baseline labs or imaging make sense for you
Review your full side effect profile so you know what is normal and what is not

During treatment:

Start at the lowest dose and follow the titration schedule your prescriber sets. Most GI side effects in SURMOUNT-1 happened during dose escalation. See Mounjaro’s dosage titration
Eat smaller meals, and do not skip meals entirely, even when appetite is suppressed
Stay hydrated
Monitor your body composition changes to make sure you are losing weight at a pace you can sustain

When to seek care right away:

Severe abdominal pain or pain that keeps getting worse
Pain that spreads from your upper abdomen to your back
Vomiting that you cannot control
Fever or chills with abdominal pain
Yellowing of skin or eyes

The Larger Safety Picture: GLP-1s and Serious Events

Pancreatitis gets outsized attention because it sounds terrifying. Placing it next to the overall safety profile helps.

In SURMOUNT-1, adverse events led to stopping treatment in 4.3%, 7.1%, and 6.2% of people on the 5 mg, 10 mg, and 15 mg doses, versus 2.6% on placebo. The most common adverse events were gastrointestinal and mostly mild to moderate. In STEP 1, 4.5% of semaglutide patients stopped because of GI events, versus 0.8% on placebo.

The SURMOUNT-5 head-to-head trial (NEJM, 2025) compared tirzepatide and semaglutide at maximum tolerated doses in 751 patients over 72 weeks. GI side effects led to stopping treatment in 2.7% on tirzepatide versus 5.6% on semaglutide, per the ACC summary.

The drugs are not without risk. But pancreatitis is one of the less likely serious outcomes in the trial data.

The Bottom Line

GLP-1 pancreatitis risk is real but rare. In the trials behind the current labels, adjudicated acute pancreatitis occurred in about 0.2% of people on tirzepatide, a rate similar to placebo, and in a handful of semaglutide patients. The FDA warning exists because of the drug class and early signals in diabetes, not because weight-loss trials showed alarming rates. If you have had pancreatitis, gallstones, or heavy alcohol use, raise it with your prescriber before you start. Know the warning signs (severe upper abdominal pain that may spread to the back, fever, persistent vomiting) and get urgent care if they appear. For most people, the more likely challenge is managing common side effects like nausea and fatigue while protecting muscle mass during weight loss.

If you are weighing providers, compare options in our provider directory or check the cheapest GLP-1 options available online.

FAQ

Can GLP-1 medications cause pancreatitis?

GLP-1 receptor agonists carry an FDA warning for acute pancreatitis, but trial rates are low. In two pooled Zepbound weight-loss trials, adjudicated acute pancreatitis occurred in 0.2% of tirzepatide patients and 0.2% of placebo patients. People with a history of pancreatitis, gallstones, or heavy alcohol use should discuss their risk with a prescriber.

How do I tell the difference between normal GLP-1 side effects and pancreatitis?

Normal GLP-1 nausea is usually mild to moderate and eases between doses. Pancreatitis causes persistent or severe upper abdominal pain that may spread to the back, often with vomiting or fever. If the pain is severe or keeps getting worse, get urgent care.

Should I get my lipase levels checked while on a GLP-1?

Ask your prescriber. The Ozempic label notes that lipase and amylase rose on average in trial patients (by 22% and 13%) without that meaning pancreatitis, so a single number can be hard to read. If you have risk factors, your prescriber may decide to check it.

Is tirzepatide or semaglutide safer for pancreatitis risk?

Neither has clearly higher pancreatitis rates in the label data. Adjudicated acute pancreatitis was about 0.2% in pooled tirzepatide weight-loss trials, and 4 semaglutide patients had it in the Wegovy weight-loss trials. The trials had different designs, so they are not a direct comparison.

Can I take a GLP-1 if I have had pancreatitis before?

A past episode is not a listed contraindication on the current tirzepatide and semaglutide labels, but the labels tell prescribers to watch for symptoms and stop the drug if pancreatitis is suspected. This needs a careful conversation with your doctor about the cause of the earlier episode and your current risk.

What we checked

This AI-assisted public-source desk check reviewed the current Zepbound, Wegovy, and Ozempic prescribing information, the SURMOUNT-1, STEP 1, and SURMOUNT-5 abstracts on PubMed, the ACC summary of SURMOUNT-5, the 2014 FDA and EMA assessment, and the NIDDK pancreatitis page on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.

Related

Guides:

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides